SCHEMBL25849055

SCHEMBL25849055

CCCCCCCCC(CCCCCC)C(=O)NCCCOCCNC(=O)c1cc(OCCNC(=O)OC(C)(C)C)cc(C(=O)NCCOCCNC(=O)C(CCCCCC)CCCCCCCC)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.44
MAPT P10636 1/20 0.44
CA12 O43570 5/20 0.41
CA1 P00915 5/20 0.41
CA2 P00918 5/20 0.41
CA9 Q16790 5/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
POLB P06746 2/20 0.41
TRIM24 O15164 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HPGD P15428 1/20 0.38
TLR2 O60603 1/20 0.38
ATM Q13315 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
CASP3 P42574 1/20 0.38
SENP7 Q9BQF6 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25848971 0.88 CNR1 (0.49) GAAMAPTCA12CA1CA2
SCHEMBL25848706 0.87 MEN1 (0.51) GAACA12CA1CA2CA9
SCHEMBL25849027 0.87 MEN1 (0.51) GAACA12CA1CA2CA9
SCHEMBL25835758 0.85 CNR1 (0.51) MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL26033023 0.84 MEN1 (0.51) GAACA12CA1CA2CA9
SCHEMBL25835742 0.82 MEN1 (0.50) GAACA12CA1CA2CA9
SCHEMBL25845557 0.81 MEN1 (0.45) GAAMAPTCA12CA1CA2
SCHEMBL31245895 0.79 CA12 (0.55) GAAMAPTCA12CA1CA2
SCHEMBL26031996 0.77 MAPT (0.44) GAAMAPTMEN1KMT2APOLB
SCHEMBL12584125 0.77 SMN1; SMN2 (0.47) GAACA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS Arrowhead Pharmaceuticals, Inc. 2023-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS CPT1B, MUSK, MYLK2 GAA 201/4885MAPT 3973/4885CA12 4744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.